5767 related articles for article (PubMed ID: 2496047)
1. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
2. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
3. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
4. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
Saiki I; Milas L; Hunter N; Fidler IJ
Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
[TBL] [Abstract][Full Text] [Related]
5. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide.
Goldbach P; Dumont S; Kessler R; Poindron P; Stamm A
Am J Physiol; 1996 Mar; 270(3 Pt 1):L429-34. PubMed ID: 8638735
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.
Dinney CP; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1992 Mar; 52(5):1155-61. PubMed ID: 1531322
[TBL] [Abstract][Full Text] [Related]
7. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
9. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
10. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.
Fidler IJ
Cancer Immunol Immunother; 1986; 21(3):169-73. PubMed ID: 3698058
[TBL] [Abstract][Full Text] [Related]
11. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
12. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
13. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
14. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
[TBL] [Abstract][Full Text] [Related]
15. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
16. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
Koff WC; Showalter SD; Hampar B; Fidler IJ
Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes.
Hockertz S; Franke G; Paulini I; Lohmann-Matthes ML
J Interferon Res; 1991 Jun; 11(3):177-85. PubMed ID: 1919076
[TBL] [Abstract][Full Text] [Related]
18. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
19. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
Hisano G; Fidler IJ
Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]